Beyond Air Subsidiary Reports Compelling Early Efficacy, Favorable Safety in Phase 1 Cancer Trial
XAIR sits 42% above its 52-week low of $0.673.
Summary
Beyond Air's subsidiary, Beyond Cancer, Ltd., announced positive interim data from its Phase 1 UNO trial for solid tumors, demonstrating early clinical activity and a favorable safety profile. The trial, involving ten heavily pretreated, end-stage cancer patients, showed that seven patients remain alive 19 to 37 months post-treatment, with two triple-negative breast cancer patients achieving no evidence of disease. This is a highly significant development for the micro-cap biotech, particularly in light of its recent 'going concern' warning, as such compelling early efficacy and safety data are critical for attracting further investment and advancing the program. The data will be presented at the AACR Annual Meeting in April, and investors will closely monitor the company's plans for subsequent clinical trial stages.
At the time of this announcement, XAIR was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5M. The 52-week trading range was $0.67 to $6.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.